Ansbert Gadicke
Ansbert Gadicke's purchase track record
Ansbert Gadicke has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/12/2026 | AKTS | $20.03M | -20.3% | +17.6% | +7.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
No Relevant News for HOWL in Last Week. The only news item in the last week concerns HALO's expanded collaboration with ARGX. This development does not involve Werewolf Therapeutics, so it has no direct impact on HOWL's operations or outlook. Investors may focus on the company's own pipeline and financials for guidance.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Kalaris Therapeutics Moves in Pre-Market Amid Low RSI. Kalaris Therapeutics was highlighted in a roundup of health care stocks moving in Wednesday's pre-market session. The stock is currently trading near its 52-week low, with the RSI indicating oversold conditions. Analysts maintain a wide range of price targets for the company, reflecting varying views on its future performance.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Cullinan delays arthritis data update to December. Cullinan Therapeutics announced it will delay its arthritis data update for zipalertinib to December due to ongoing safety concerns. This decision follows the release of strong Phase 3 lung cancer data, which initially saw the stock drop 18.2%. The company also confirmed plans for Q4 2026 updates across three T cell engager programs.
Transaction History
| AKTS | ▼ Sell | Other | 1,314,262 | — | 1/12/2026 | View on chart |
| AKTS | ▼ Sell | Other | 5,914,197 | — | 1/12/2026 | View on chart |
| AKTS | ▼ Sell | Other | 1,577,119 | — | 1/12/2026 | View on chart |
| AKTS | ▲ Buy | Open Market | 1,112,777 | $20.0M | 1/12/2026 | View on chart |
| HOWL | ▼ Sell | Open Market | 83,230 | $81K | 12/4/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 57,225 | $50K | 12/3/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 59,277 | $53K | 12/2/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 60,917 | $57K | 12/1/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 20,277 | $20K | 11/28/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 60,733 | $60K | 11/26/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 42,533 | $39K | 11/25/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 88,802 | $87K | 11/24/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 64,331 | $53K | 11/21/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 41,152 | $37K | 11/20/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 66,324 | $62K | 11/19/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 52,627 | $49K | 11/18/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 57,061 | $54K | 11/17/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 61,640 | $57K | 11/14/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 90,951 | $89K | 11/13/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 40,669 | $44K | 11/12/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 55,810 | $64K | 11/11/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 48,570 | $57K | 11/10/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 68,480 | $76K | 11/7/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 54,452 | $66K | 11/6/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 47,950 | $58K | 11/5/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 140,488 | $171K | 11/4/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 94,063 | $121K | 11/3/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 114,044 | $146K | 10/31/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 86,936 | $124K | 10/30/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 134,240 | $208K | 10/29/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 69,068 | $113K | 10/28/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 72,709 | $125K | 10/27/2025 | View on chart |
| HOWL | ▼ Sell | Other | 50,873 | $5K | 3/27/2025 | View on chart |
| HOWL | ▼ Sell | Open Market | 4,386 | $5K | 3/27/2025 | View on chart |
| KLRS | ▲ Buy | Grant | 3,253,796 | $15.0M | 7/28/2022 | View on chart |
| CGEM | ▼ Sell | Open Market | 432 | $13K | 9/16/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 3,124 | $91K | 9/16/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 888 | $26K | 9/15/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 6,425 | $187K | 9/15/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 982 | $29K | 9/14/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 7,106 | $207K | 9/14/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 3,595 | $105K | 9/13/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 497 | $14K | 9/13/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 820 | $24K | 9/10/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 5,931 | $172K | 9/10/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 1,898 | $56K | 9/9/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 13,727 | $403K | 9/9/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 1,499 | $44K | 9/8/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 10,842 | $316K | 9/8/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 3,465 | $101K | 9/7/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 25,067 | $728K | 9/7/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 1,760 | $52K | 9/3/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 12,731 | $377K | 9/3/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 2,178 | $64K | 9/2/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 15,757 | $464K | 9/2/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 790 | $23K | 9/1/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 5,714 | $168K | 9/1/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 177 | $5K | 8/31/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 1,285 | $38K | 8/31/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 215 | $6K | 8/31/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 1,553 | $47K | 8/31/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 4,285 | $126K | 8/30/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 31,001 | $908K | 8/30/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 1,846 | $54K | 8/27/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 13,357 | $389K | 8/27/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 237 | $7K | 8/25/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 1,713 | $50K | 8/25/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 7,025 | $207K | 8/24/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 50,882 | $1.5M | 8/24/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 7,376 | $215K | 8/23/2021 | View on chart |
| CGEM | ▼ Sell | Open Market | 53,359 | $1.6M | 8/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
AKTS launches second Phase 1b trial for AKY-2519
Aktis Oncology announced the start of a second Phase 1b clinical trial for its AKY-2519 candidate. The trial follows earlier testing and moves the drug further along the development pathway. This progress adds to the company's pipeline activity while the stock remains in a low RSI region, indicating recent price weakness.
AKTS launches second Phase 1b trial for AKY-2519. Aktis Oncology announced the start of a second Phase 1b clinical trial for its AKY-2519 candidate. The trial follows earlier testing and moves the drug further along the development pathway. This progress adds to the company's pipeline activity while the stock remains in a low RSI region, indicating recent price weakness.